Product Information
ONFI 2.5 MG/ML SUSPENSION is a brand product labeled by Lundbeck Pharmaceuticals LLC, priced at $12.4731 per ML under NDC 67386031321. Its NADAC has been published 663 times since Jan 22, 2014.
FDA first approved this application on Dec 14, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the clobazam market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
2.5 mg/mL
Manufacturer
Lundbeck Pharmaceuticals LLCNDC
67386031321
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLOBAZAMApproval Type
New Drug (NDA)
FDA Application
NDA203993FDA Approved
12/14/2012
TE Code
AB
On Market Since
12/14/2012
Pharmacological Classes
Price Statistics
The NADAC for ONFI 2.5 MG/ML SUSPENSION has been published 663 times since Jan 22, 2014, and over the history we have for it it has risen 190.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.4731 per ML |
|---|---|
| All-time high | $12.5514 (May 15, 2024) |
| All-time low | $4.2860 (Feb 19, 2014) |
| 52-week high | $12.4905 |
| 52-week low | $12.4722 |
| Median price | $9.2183 |
| Average price | $9.0208 |
| Largest weekly change | +15.0% (Nov 26, 2014) |
| Weeks tracked | 663 |
| Tracking since | Jan 22, 2014 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lundbeck Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
clobazam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ONFI 2.5 MG/ML SUSPENSION?
The current National Average Drug Acquisition Cost (NADAC) for ONFI 2.5 MG/ML SUSPENSION, manufactured by Lundbeck Pharmaceuticals LLC, is $12.4731 per ML (NDC 67386031321), effective Sep 30, 2026.
How has the price of ONFI 2.5 MG/ML SUSPENSION changed over time?
Over the history we have for it, the NADAC for ONFI 2.5 MG/ML SUSPENSION has risen 190.2%. It has been tracked across 663 weekly CMS publications since Jan 22, 2014.
What are the highest and lowest recorded NADAC prices for ONFI 2.5 MG/ML SUSPENSION?
Since Jan 22, 2014, the NADAC for ONFI 2.5 MG/ML SUSPENSION has ranged from a low of $4.2860 (Feb 19, 2014) to a high of $12.5514 (May 15, 2024), with a median of $9.2183 per ML.
Are there cheaper alternatives to ONFI 2.5 MG/ML SUSPENSION?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CLOBAZAM 2.5 MG/ML SUSPENSION, is $0.1730 per ML — about 99% below ONFI 2.5 MG/ML SUSPENSION.
Who manufactures ONFI 2.5 MG/ML SUSPENSION?
ONFI 2.5 MG/ML SUSPENSION (NDC 67386031321) is labeled by Lundbeck Pharmaceuticals LLC, and CMS classifies it as a brand product.